Document is current
Any future updates will be listed below
-
Authors
Krug, David https://orcid.org/0000-0001-8811-5416
Imhoff, Detlef
Haidenberger, Alfred
Heßler, Nicole
Schäfer, Jane
Huttenlocher, Stefan
Chatzikonstantinou, Georgios
Fürweger, Christoph
Ramm, Ulla
König, Inke R.
Chun, Felix
Staehler, Michael
Rödel, Claus
Muacevic, Alexander
Vonthein, Reinhard
Dunst, Jürgen
Blanck, Oliver
-
Funding
Funding for this research was provided by:
Dr. Rurainski Stiftung
Saphir Medical Engineering Group
Universitätsklinikum Schleswig-Holstein - Campus Kiel
- License Information
-
More Information
Article History
Received: 16 November 2022
Accepted: 4 January 2023
First Online: 9 February 2023
Declarations
:
: D. Krug has received honoraria from MSD Sharp & Dohme and Pfizer as well as research funding from Merck KGaA, outside the submitted work. A. Muacevic and C. Fürweger previously received speaker fees from Accuray. O. Blanck is the section editor for medical physics of the journal <i>Strahlentherapie und Onkologie</i>. D. Imhoff, A. Haidenberger, N. Heßler, J. Schäfer, S. Huttenlocher, G. Chatzikonstantinou, U. Ramm, R. König, F. Chun, M. Staehler, C. Rödel, R. Vonthein, and J. Dunst declare that they have no competing interests.
: The study was approved by the ethics committee of the University of Lübeck (leading ethics committee, file number 13–052) as well as the local ethics committees at the participating sites. The trial was also approved by the federal regulatory authority, the <i>Bundesamt für Strahlenschutz</i> (reference number Z5–22463/2–2013-031). The study is monitored by ZKS Lübeck, Germany (protocol number ZKS-121-003). The trial was accredited by the Working Group Radiation Oncology of the German Cancer Society (trial-ID ARO 2013-06). All patients provided written informed consent before enrolment in the clinical trial.
